Product Description
A nucleoside analogue used in the treatment of chronic hepatitis B for patients with active viral replication, histological evidence of active disease, or persistent elevations in liver transaminases.
AI Product Description
*The following content is generated by AI and is for reference only.
Entecavir Dispersible Tablets are a specialized pharmaceutical formulation designed for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients. As a potent guanosine nucleoside analogue, Entecavir works by selectively inhibiting the viral DNA polymerase, thereby blocking the replication of the hepatitis B virus. This mechanism significantly reduces viral load, improves liver function tests, and decreases the risk of disease progression to cirrhosis or hepatocellular carcinoma. The dispersible tablet form offers distinct advantages over standard tablets, particularly for children, elderly individuals, or patients with swallowing difficulties, as it can be easily dissolved in water to ensure accurate dosing and improved compliance.
Patients prescribed this medication must adhere strictly to their dosing schedule to maintain therapeutic efficacy. It is crucial to take Entecavir on an empty stomach, typically at least two hours before or after a meal, as food can significantly reduce drug absorption. Treatment duration is often long-term; abrupt discontinuation may lead to severe acute exacerbations of hepatitis, so any changes in therapy must be supervised by a healthcare provider. Before initiating treatment, clinicians should assess renal function, as dosage adjustments are necessary for patients with impaired kidney function. Additionally, caution is advised for patients with HIV co-infection, as monotherapy with entecavir may select for HIV resistance mutations if the underlying HIV is not properly managed with combination antiretroviral therapy.
Common side effects include headache, fatigue, dizziness, and nausea. While generally well-tolerated, rare but serious adverse events such as lactic acidosis and severe hepatomegaly with steatosis have been reported. Pregnant or breastfeeding women should consult their physician regarding potential risks versus benefits. Regular monitoring of HBV DNA levels, liver enzymes, and renal parameters is essential throughout the course of therapy to evaluate response and detect any emerging complications. By effectively suppressing viral replication, Entecavir Dispersible Tablets play a vital role in managing chronic hepatitis B and improving long-term patient outcomes.